Skyclarys Rejected Despite Hope | Cork News

The HSE has rejected funding for Skyclarys, a life-changing drug for Friedreich’s ataxia—a rare, devastating disease affecting just 200 people in Ireland. Though a later review backed the drug’s value, its €280,000 annual cost proved too steep. Craig Coady, grieving the loss of his son Rory and fighting for his younger son Paudie, called the decision “shameful,” urging the Taoiseach to intervene—especially since 11 countries already fund it. The HSE insists on balancing clinical need with budget realities, but families say this choice feels like abandoning those who need it most. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8df81eb071022f7b